SangAsept – Revolutionizing Sepsis Care
SangAsept is a unique process that treats blood outside the body and generates an immediate effect on bacteria present in blood.
New technology set to revolutionize sepsis treatment, save lives and reduce antibiotic resistance
Sepsis affects 49 million people annually and has a high mortality rate. Treatments rely heavily on antibiotics, contributing to antibiotic resistance. Sangair has developed SangAsept, a technology that reduces E. coli and Pseudomonas in the blood and lowers inflammation, offering improved care and reducing the reliance on antibiotics.
“If SangAsept can show that it saves One life with severe Sepsis, it will be a standard equipment in every Intensive Care Unit in the world. This may become the first real alternative and innovation since the discovery of Antibiotics to treat a bacterial infection in blood.”
Press Releases
Clear effect in pre-clinical study
Sangair team can share some exciting news. Our ongoing pre-clinical study shows a clear effect. SangAspet™ lowers the number of…
Sangair patent is approved in Canada
The intellectual property family has expanded with an approved patent application in Canada, pertaining to ozonation of blood, and more…
Sangair strengthens the board of Directors
At the annual bord meeting on the 16th of June the shareholders added two new board members, Susanne Olausson and…